News
ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...
: WHO-approved HIV preventive drug Lenacapavir to be rolled out next year to allow for changes in existing guidelines and ...
Kenya is among nine African countries selected to introduce Lenacapavir, a groundbreaking long-acting injectable HIV ...
GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...
Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...
15h
AllAfrica on MSNMomentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To ActionNew WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...
The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...
We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
South Africa's government has estimated that universities and science councils could lose about $107 million in US research funding over the next five years due to the aid cuts, which affect not only ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results